U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Consumer-Directed Broadcast Advertisements Questions and Answers
  1. Regulatory Information

GUIDANCE DOCUMENT

Consumer-Directed Broadcast Advertisements Questions and Answers August 1999

Final

Consumer-Directed Broadcast Advertisements Questions and Answers

Issued by:
Guidance Issuing Office
Center for Veterinary Medicine
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research

Q: What are the differences, if any, between the draft guidance and the final guidance concerning consumer-directed (direct-to-consumer or DTC) broadcast advertisements?

A: The final guidance does not differ substantially from the draft guidance. Minor revisions include: (1) reformatting the assumptions underlying what constitutes a compliant broadcast advertisement in general; (2) deleting the option under the toll-free telephone component of the adequate provision approach to offer to fax product labeling to consumers; (3) emphasizing the need for the print advertisement component of the adequate provision approach to be broadly disseminated; (4) acknowledging that the print brochures alternative component of the adequate provision approach was likely to be feasible only when broadcasting was fairly limited in scope; (5) acknowledging explicitly that healthcare providers other than physicians and pharmacists can be sources of additional human drug product information; and (6) adding a discussion to clarify the differences in satisfactory adequate provision approaches for telephone advertisements, compared with television or radio advertisements.


Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.